Prevalence, Trends, and Mortality of Low Muscle Mass and Its Association With Metabolic Diseases in the United States Population
Open Access
- 1 January 2026
- journal article
- Published by Wiley in JCSM Communications
- Vol. 9 (1)
Abstract
Background: Low muscle mass is increasingly recognized to extend beyond aging and is closely linked to metabolic dysfunction. Its population‐level burden, ethnic disparities, metabolic clustering and mortality impact in the United States remain incompletely characterized. Methods: We analysed data from NHANES 1999–2016, including adults aged ≥ 18 years with dual energy X‐ray absorptiometry (DEXA) measures. Low muscle mass was defined using established appendicular lean mass criteria adjusted for body size. Prevalence estimates were weighted to represent the US population. Temporal trends were assessed using Joinpoint regression, and mortality outcomes (all‐cause, cardiovascular and cancer‐related) were evaluated. Results: Low muscle mass affected 8.35% (95% CI: 7.84% to 8.90% of US adults and remained stable over time (average annual percent change [AAPC]: −1.475, 95% CI: −3.853 to 0.961, p = 0.233). Mexican Americans had the highest prevalence (18.60%, 95% confidence interval [CI]: 15.64 to 21.98, p < 0.001), while non‐Hispanic Blacks had the lowest (2.96%, 95% CI: 2.36 to 3.70, p < 0.001). Individuals with low muscle mass were older, had higher body mass index (BMI) and exhibited greater metabolic dysfunction, including hypertension (50.44%), diabetes (23.10%) and Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) (56.58%). Over a median follow‐up of 166 months, low muscle mass was associated with increased all‐cause mortality (adjusted hazard ratio: 1.43, 95% CI: 1.30 to 1.58, p < 0.001), though cardiovascular and cancer mortality associations attenuated after adjustment. The mortality risk was amplified when low muscle mass coexisted with diabetes, obesity, hypertension or hyperlipidaemia. Conclusions: Low muscle mass affects nearly one in 12 US adults and is strongly intertwined with metabolic dysfunction. Our findings suggest that low muscle mass functions primarily as a marker of adverse metabolic health rather than an isolated predictor of mortality. Its coexistence with cardiometabolic disease confers substantially increased mortality risk, underscoring the need to identify, diagnose and manage low muscle mass within a metabolic disease framework rather than as an isolated muscle disorder.Keywords
This publication has 24 references indexed in Scilit:
- High Global Prevalence of Steatotic Liver Disease and Associated Subtypes: A Meta-analysisClinical Gastroenterology and Hepatology, 2025
- Baroreflex Function in Cardiovascular DiseaseJournal of Cardiac Failure, 2024
- Sarcopenia and Sarcopenic Obesity and Mortality Among Older PeopleJAMA Network Open, 2024
- Myosteatosis in nonalcoholic fatty liver disease: An exploratory studyClinics and Research in Hepatology and Gastroenterology, 2021
- Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake2020
- Sarcopenia and its association with falls and fractures in older adults: A systematic review and meta‐analysisJournal of Cachexia, Sarcopenia and Muscle, 2019
- Optimal threshold of controlled attenuation parameter with MRI‐PDFF as the gold standard for the detection of hepatic steatosisHepatology, 2017
- Sarcopenia and mortality among a population‐based sample of community‐dwelling older adultsJournal of Cachexia, Sarcopenia and Muscle, 2015
- Multiple imputation of missing dual‐energy X‐ray absorptiometry data in the National Health and Nutrition Examination SurveyStatistics in Medicine, 2010
- Skeletal muscle hypertrophy and atrophy signaling pathwaysThe International Journal of Biochemistry & Cell Biology, 2005